Dear Ms. Luther:

Please refer to your supplemental new drug applications dated August 16, 1999, received August 18, 1999 (S-002) and May 17, 2002, received May 21, 2002 (S006), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for SORIATANE ® (acitretin) Capsules, 10 mg and 25mg.

We acknowledge receipt of your submissions dated March 6, February 27, 11, 6, 2, 2003, December 19, 17, 4, 2, 2002 and November 26, 2002.

These supplemental new drug applications provide for revisions which include changes to the Boxed Warning, Contraindications, Warnings, Precautions, Overdosage, Drug Interactions, Adverse Reactions, the Informed Consent Form for Females, the addition of Clinical Studies and Geriatric sections, a Medication Guide, and revisions to the Soriatane Pregnancy Prevention program booklet. This approval also contains wording for the Dear Professional Letters.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text. Please note on page 5 of the Package Insert placement of the following table under Information for Males Taking Soriatane:

<table>
<thead>
<tr>
<th>Timing of paternal acitretin treatment relative to conception</th>
<th>Delivery of healthy neonate</th>
<th>Spontaneous abortion</th>
<th>Induced abortion</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>At time of conception</td>
<td>5*</td>
<td>5</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Discontinued ~ 4 weeks prior</td>
<td>0</td>
<td>0</td>
<td>1***</td>
<td>1</td>
</tr>
<tr>
<td>Discontinued ~ 6-8 months prior</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

* Four of 5 cases were prospective

**With malformation pattern not typical of retinoid embryopathy (bilateral cystic hygromas of neck, hypoplasia of lungs bilateral, pulmonary atresia, VSD with overriding truncus arteriosus)

Please include the appropriate reference for the above data and re-number all subsequent references accordingly.

FDA considers the patient brochure (including Pregnancy Prevention Program [PPP] booklet), like the Informed Consent Form and the Medication Guide on which it is based, part of the approved labeling for Soriatane. As such, the FPL for the PPP booklet should reflect the revisions in the approved Informed Consent Form and the approved wording for the Medication Guide.

Your submitted plan for implementing new labeling and the Medication Guide into the marketplace is acceptable; please make every effort to exchange patient materials and package inserts in prescribers’ offices at next marketing representative call.
As a reminder, FDA expects the post-marketing agreement in the original 1997 approval action to be completed as agreed upon at that time (study of acitretin and etretinate levels in 100 women of child-bearing potential).

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, immediate container, and carton labels) and must be formatted in accordance with the requirements of 21 CFR 201.66. Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated “FPL for approved supplement NDA 19-821/S-002 AND S-006.” Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Dermatologic and Dental Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter(s) communicating important information about this drug product (such as the agreed upon “Dear Health Care Professional” letters), we request that you submit a copy of the letter(s) to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kalyani Bhatt, Regulatory Project Manager, at (301) 827-2020.

Sincerely,

Kathryn A. O’Connell, M.D., Ph.D.
Medical Officer
acting for
Jonathan K. Wilkin, M.D.
Director
Division of Dermatologic & Dental Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Katherine OConnell
4/18/03 03:54:30 PM
acting today for Jonathan Wilkin, M.D., Division Director